ArticleCancer medicine2026
Trends in Survival and Cure Indicators of Thin and Thick Cutaneous Malignant Melanoma in Italy.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Trends in Survival and Cure Indicators of Thin and Thick Cutaneous Malignant Melanoma in Italy.Cancer medicine · 2026Article
- Screening children and adolescents for cutaneous malignant melanoma: the impossible trade-off between life-years saved and unnecessary biopsies.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors.
Funding
Abstract
backgroundIn Italy, cure indicators of cutaneous malignant melanoma according to Breslow tumour thickness have never been assessed.
objectivesTo evaluate the time trend in 1-year net survival (NS), 5|1-year conditional NS (CNS) and cure fraction (CF).
methodsData from 10 cancer registries and 13,377 patients aged 15-74 years were used. Five|1-year CNS was defined as the probability of surviving 5 years given that the patient has survived 1 year. CF was defined as the proportion of patients with the same life expectancy as the general population. One-year NS and 5|1-year CNS were contrasted between 2013-2017 and 2003-2007, and CF between 2015 and 2005.
resultsFor lesions up to 4 mm thick, 1-year NS reached a level > 98.0%. In 2013-2017, 5|1-year CNS was above 90% for men and women with lesions up to 2.0 mm thick and increased markedly for men with lesions > 2.0-4.0 mm thick (65.1% to 82.4%) and > 4.0 mm thick (57.6% to 69.4%). The CF of patients with a melanoma ≤ 1.0 mm thick was approximately 100% in both sexes, and nearly doubled from 2005 to 2015 (28% to 54%) for men aged 55-74 years with a melanoma > 4.0 mm thick.
conclusionsPatients with a melanoma ≤ 1 mm thick have the same life expectancy as the general population. The increase in the CF of men with thick lesions supports the hypothesis that novel therapies, approved in Italy since 2013, offer the possibility of cure.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.